<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670070</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GSCL003</org_study_id>
    <nct_id>NCT02670070</nct_id>
  </id_info>
  <brief_title>BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of
      gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the safety/tolerability and pharmacokinetics(AUC and Cmax) of the
      combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component
      administered alone in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast, Cmax</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate AUClast/Cmax of gemigliptin and rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate AUCinf of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate Tmax of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate t1/2 of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate CL/F of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>To evaluate metabolic ratio of gemigliptin, LC15-0636 of gemigliptin metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax</measure>
    <time_frame>up to 72h post-dose</time_frame>
    <description>This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Coadministration of G+R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coadministration of gemigliptin 50mg and rosuvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination G/R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of gemigliptin 50mg / rosuvastatin 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin 50mg, rosuvastatin 20mg</intervention_name>
    <description>gemigliptin/rosuvastatin 50/20mg</description>
    <arm_group_label>Coadministration of G+R</arm_group_label>
    <arm_group_label>Combination G/R</arm_group_label>
    <other_name>Zemiglo, Cresto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19 to 45, healthy male subjects(at screening)

          -  BMI between 18.0 - 27.0

          -  FPG 70-125mg/dL glucose level(at screening)

          -  Subject who totally understand the progress of this clinical trials, make decision by
             his free will, and signed a consent form to follow the progress.

        Exclusion Criteria:

          -  Subject who has past or present history of any diseases following below.(liver
             including hepatitis virus carrier, kidney,
             Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)

          -  Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis)
             surgery.(appendectomy, hernioplasty are not included)

          -  Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)

          -  Subject who already participated in other trials in 2months

          -  Subject who had whole blood donation in 2 months, or component blood donation in 1
             month or transfusion in 1 month currently.

          -  Heavy smokers.(&gt;10 cigarettes per day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

